Bedaquiline for tuberculosis, multidrug-resistant

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 20 Mar 2026: Trial registered, NCT07486024
  2. 11 Sep 2026: Trial started, NCT07486024

The trials

NCT07486024: Feasibility of the Application of a New Six-month Treatment for Multidrug-resistant Tuberculosis (MDR-TB) Patients in France (FAST-MDR)

State
Under way
Phase
Phase 3
People
55 planned
Started
11 Sep 2026
Primary completion
Aug 2030
Arms
Bedaquiline - 400 mg, Bedaquiline - 200 mg
Results
None posted
  1. 20 Mar 2026: Trial registered
  2. 11 Sep 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Bedaquiline (B), Bedaquiline Oral Tablet.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.